LY2183240

LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM) . LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively[1][2] [3].

Product Specifications

CAS Number

[874902-19-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; FAAH

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/LY2183240.html

Concentration

10mM

Purity

98.01

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N(C)C)N1N=NN=C1CC(C=C2)=CC=C2C3=CC=CC=C3

Molecular Formula

C17H17N5O

Molecular Weight

307.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Moore SA, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A. 2005;102 (49) :17852-17857.|[2]Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc. 2006 Aug 2;128 (30) :9699-704.|[3]Maione S, et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. Br J Pharmacol. 2008 Nov;155 (5) :775-82.|[4]Pelorosso FG, et al. The endocannabinoid anandamide inhibits kinin B1 receptor sensitization through cannabinoid CB1 receptor stimulation in human umbilical vein. Eur J Pharmacol. 2009 Jan 5;602 (1) :176-9.|[5]Powers MS, et al. Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. Psychopharmacology (Berl) . 2010 Dec;212 (4) :571-83.|[6]Sun L, et al. Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation. Eur J Pain. 2017 May;21 (5) :804-814.